Last reviewed · How we verify
AZD0120 - Regimen 1
At a glance
| Generic name | AZD0120 - Regimen 1 |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) (PHASE3)
- A Study of AZD0120 in Autoimmune Diseases (PHASE1)
- An Open-label Study of AZD0120 in Adults With Multiple Sclerosis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD0120 - Regimen 1 CI brief — competitive landscape report
- AZD0120 - Regimen 1 updates RSS · CI watch RSS
- AstraZeneca portfolio CI